Showing 2191-2200 of 5909 results for "".
- Ophtec’s Preloaded Capsular Tension Ring Ringject Receives Approval in Chinahttps://modernod.com/news/ophtecs-preloaded-capsular-tension-ring-ringject-receive-approval-in-china/2476275/Ophtec was granted CFDA approval for the preloaded capsular tension ring (CTR) Ringject in China. Ringject is a preloaded, single use capsular tension ring designed to be self-loading for surgical convenience. CTRs were originally introduced to strengthen the zonule in eyes with zonular de
- Oculogica Receives FDA Marketing Approval for EyeBOX, the First Noninvasive, Baseline-Free Test for Concussionhttps://modernod.com/news/oculogica-receives-fda-marketing-approval-for-eyebox-the-first-noninvasive-baseline-free-test-for-concussion/2476218/Oculogica announced that the FDA granted their De Novo request for the commercialization of EyeBOX, the first noninvasive, baseline-free tool to aid in the diagnosis of concussion. Oculogica plans to market the device for use in pediatrics ages 5 and older and adults up to 67 years o
- Oculis In-Licenses Phase 2 Topical Anti-TNF Alpha Antibody From Novartishttps://modernod.com/news/oculis-in-licenses-phase-2-topical-anti-tnf-alpha-antibody-from-novartis/2476220/Oculis has entered into an agreement to in-license a novel topical anti-TNF alpha antibody from Novartis. Terms of the deal were not disclosed. The compound, named LME 636, is based on a proprietary single-chain antibody fragment technology specifically de
- Novaliq Announces Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-positive-topline-results-for-its-seecase-phase-2-trial-of-nov03-for-the-treatment-of-patients-with-dry-eye-disease/2479732/Novaliq announces positive topline results for its SEECASE phase 2 clinical trial of NOV03 for the treatment of dry eye disease (DED) in more than 300 patients. NOV03 (100% perfluorohexyloctane) is a preservative-free ophthalmic solution and the first drug developed to treat evaporative DE
- RGN-259 (Tβ4) Improves Clinically Important Dry Eye Efficacies in Comparison with Prescription Drugshttps://modernod.com/news/rgn-259-tceb24-improves-clinically-important-dry-eye-efficacies-in-comparison-with-prescription-drugs/2480019/RegeneRx Biopharmaceuticals announced that a new study was published comparing RGN-259 with currently approved prescription products for dry eye syndrome (DES). In the study, researchers demonstrated that after 10 days of treatment RGN-259 performed equal to or better than cyclosporine A (Restasi
- Oculus Incorporates Oculus Brasil in São Paulohttps://modernod.com/news/oculus-incorporates-oculus-brasil-in-sao-paulo/2480050/Oculus Optikgeräte, Germany, has incorporated Oculus Brasil Comercio Importação Exportação e Serviços de Equipamentos Médicos LTDA as its 10th international subsidiary. Located in São Paulo, Oculus Brasil will support new and existing customers throughout Brazil. Oculus Optikger
- NuSight Medical Launches NuLids for the Treatment of Dry Eyehttps://modernod.com/news/nusight-medical-launches-nulids-for-the-treatment-of-dry-eye/2480078/NuSight Medical has introduced The NuLids System, a doctor-prescribed, home-use medical device that efficiently treats dry eye by gently stimulating, de-capping, and rejuvenating the meibomian glands to a healthier state. The system was introduced at the American Optometric Association mee
- IDOC Launches Easyvision Private Label Contact Lens Portfolio for Independent Optometristshttps://modernod.com/news/idoc-launches-easyvision-private-label-contact-lens-portfolio-for-independent-optometrists/2486489/Key Takeaways easyvision is a new private label daily disposable contact lens portfolio from IDOC, manufactured by CooperVision
- SignaBlok Receives Orphan Drug Designation From FDA for a First-in-Class TREM-1 Peptide Inhibitor for the Treatment of Retinopathy of Prematurityhttps://modernod.com/news/signablok-receives-orphan-drug-designation-from-fda-for-a-first-in-class-trem-1-peptide-inhibitor-for-the-treatment-of-retinopathy-of-prematurity/2486398/Key Takeaways The FDA granted Orphan Drug Designation to SignaBlok’s triggering receptor expressed on myeloid cells 1 peptide inhibitor for treating retinopathy of prematurity According to the company, the designation highlights the therapy’s potential as a
- TP-03 Now Approved in China for the Treatment of Demodex Blepharitishttps://modernod.com/news/tp-03-now-approved-in-china-for-the-treatment-of-demodex-blepharitis/2486355/Key Takeaways TP-03 (XDEMVY) has been approved in China by the NMPA for treating Demodex blepharitis, marking a major expansion beyond th